Study finds most weight loss drugs including Wegovy and Mounjaro ‘do not improve quality of life’
In total, 262 studies involving 99,791 individuals were examined
- Center-left1
- Right1
no rewrites detected — all voices distinct
Summary
In total, 262 studies involving 99,791 individuals were examined. Mounjaro led to the highest fat lost (by 25.7 per cent) but also the biggest loss of lean body mass such as muscle (8.3 per cent). Mounjaro reduced the heart failure risk by 51 per cent.
Furthermore, No drug convincingly reduced kidney failure or showed clinically-important improvements in quality of life, researchers, including from China, Norway and Canada, said. Emerging drugs – including retatrutide, ecnoglutide and mazdutide – showed large effects on weight loss but were supported by low or very low certainty evidence, researchers said. A review of existing data on weight-loss medicines concluded that while people lose weight, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life.
In addition, Some healthcare providers are offering the first month's treatment for as little as £60 as they battle for market share following the drug's long-awaited rollout in the UK. Discussions about making the treatment available on the NHS are understood to be taking place soon, although no timetable has yet been announced. Moreover, greater weight loss was linked to an increased likelihood of side effects, such as stomach problems and the loss of lean muscle mass.
Cross-referenced from 2 sources.
Factual coreconfirmed by several independent voices
In total, 262 studies involving 99,791 individuals were examined.
reliability moderate2/2 sourcesMounjaro led to the highest fat lost (by 25.7 per cent) but also the biggest loss of lean body mass such as muscle (8.3 per cent).
reliability moderate2/2 sourcesMounjaro reduced the heart failure risk by 51 per cent.
reliability moderate2/2 sourcesNo drug convincingly reduced kidney failure or showed clinically-important improvements in quality of life, researchers, including from China, Norway and Canada, said.
reliability moderate2/2 sourcesEmerging drugs – including retatrutide, ecnoglutide and mazdutide – showed large effects on weight loss but were supported by low or very low certainty evidence, researchers said.
reliability moderate2/2 sourcesA review of existing data on weight-loss medicines concluded that while people lose weight, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life.
reliability moderate2/2 sources
Reported detailssecondary facts, each attributed to its source
Some healthcare providers are offering the first month's treatment for as little as £60 as they battle for market share following the drug's long-awaited rollout in the UK.
according to Daily MailDiscussions about making the treatment available on the NHS are understood to be taking place soon, although no timetable has yet been announced.
according to Daily MailMoreover, greater weight loss was linked to an increased likelihood of side effects, such as stomach problems and the loss of lean muscle mass.
according to The Independent
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources2 sources cross-checked
Center-left1
Right1